Last 23 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 10.84 | 29.64 | 19.00 | 9.54 | 24.72 | 10.99 | 8.99 | 17.29 | 21.90 | 10.69 | 47.24 | 35.60 | 4.23 | 17.38 | 23.19 | 25.94 | 48.62 | 19.68 | 52.16 | 88.72 | 68.86 |
| — | +169.8% | +111.3% | -44.8% | +12.9% | +2.8% | -81.0% | -51.5% | +417.5% | -38.5% | +103.7% | +37.3% | -91.3% | -11.7% | -55.5% | -70.8% | -29.4% | — | — | — | — | |
| P/B Ratio | 0.93 | 1.81 | 1.79 | 1.23 | 1.53 | 0.71 | 0.39 | 0.57 | 0.63 | 0.48 | 1.34 | 1.38 | 1.01 | 0.97 | 1.17 | 1.27 | 1.98 | 0.95 | 1.49 | 2.34 | 2.71 |
| — | +156.8% | +358.3% | +116.7% | +143.1% | +47.8% | -70.9% | -58.7% | -37.3% | -50.7% | +14.5% | +8.0% | -49.3% | +2.1% | -21.9% | -45.6% | -26.8% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.3% | 100.0% | 72.9% | 100.0% | -919.2% | 51.3% | 25.9% | -1337.8% | -1373.4% | 75.3% | 70.8% | 44.5% | -20.8% | -605.8% | -634.1% | -597.1% | 100.0% | -438.6% | -422.7% | 89.3% | -298.1% |
| — | +94.8% | +181.3% | +107.5% | +33.1% | -31.8% | -63.4% | -3105.1% | -6502.3% | +112.4% | +111.2% | +107.5% | -120.8% | -38.1% | -50.0% | -768.4% | +133.5% | -538.6% | +21.9% | +108.0% | — | |
| Operating Margin | -1220.5% | -1690.4% | -1096.4% | -722.0% | -1337.6% | -1784.0% | -1823.8% | -1871.7% | -1889.2% | -1255.8% | -1893.9% | -1052.3% | -61.8% | -875.3% | -888.5% | -828.2% | -803.4% | -678.2% | -782.8% | -797.4% | -468.1% |
| — | +5.2% | +39.9% | +61.4% | +29.2% | -42.1% | +3.7% | -77.9% | -2954.9% | -43.5% | -113.1% | -27.1% | +92.3% | -29.1% | -13.5% | -3.9% | -71.6% | +37.3% | +5.8% | +48.4% | — | |
| Net Margin | -1327.4% | -1619.9% | -1046.5% | -672.1% | -1253.3% | -2028.4% | -1699.6% | -1708.7% | -1713.6% | -1088.3% | -1697.6% | -969.8% | -42.3% | -786.1% | -800.8% | -731.0% | -806.8% | -636.9% | -716.5% | -722.1% | -527.4% |
| — | +20.1% | +38.4% | +60.7% | +26.9% | -86.4% | -0.1% | -76.2% | -3954.0% | -38.4% | -112.0% | -32.7% | +94.8% | -23.4% | -11.8% | -1.2% | -53.0% | +34.3% | +13.6% | +51.7% | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -79.0% | -24.3% | -22.4% | -20.1% | -17.9% | -28.2% | -17.0% | -13.3% | -11.7% | -11.5% | -11.6% | -9.0% | -3.0% | -10.8% | -9.7% | -8.6% | -7.9% | -7.4% | -5.0% | -4.7% | -11.8% |
| — | +14.0% | -31.5% | -51.0% | -52.6% | -144.7% | -46.8% | -47.6% | -291.4% | -7.0% | -19.6% | -4.2% | +62.2% | -45.3% | -92.7% | -85.1% | +32.6% | — | — | — | — | |
| ROA | -60.6% | -16.6% | -15.3% | -14.1% | -13.2% | -21.9% | -13.6% | -10.8% | -9.7% | -9.7% | -9.8% | -7.8% | -2.5% | -8.5% | -7.8% | -7.0% | -6.5% | -6.2% | -4.3% | -4.1% | -6.8% |
| — | +23.9% | -12.0% | -31.0% | -37.0% | -126.3% | -38.6% | -39.2% | -290.2% | -14.2% | -26.4% | -11.0% | +61.9% | -37.6% | -81.0% | -71.0% | +3.9% | +29.8% | +66.7% | +90.0% | — | |
| ROIC | -51.0% | -17.6% | -15.5% | -14.6% | -13.7% | -18.7% | -13.5% | -10.8% | -9.9% | -10.5% | -10.3% | -8.4% | -4.0% | -10.2% | -8.9% | -8.5% | -7.5% | -8.3% | -7.8% | -26.0% | — |
| — | +5.9% | -15.1% | -34.8% | -37.7% | -79.2% | -30.4% | -28.0% | -149.5% | -2.6% | -16.0% | +0.7% | +46.7% | -23.4% | -14.0% | +67.4% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.27 | 0.26 | 0.22 | 0.18 | 0.16 | 0.12 | 0.10 | 0.10 | 0.09 | 0.08 | 0.07 | 0.07 | 0.10 | 0.10 | 0.09 | 0.09 | 0.08 | 0.08 | 0.00 | 0.00 |
| — | +74.6% | +118.8% | +112.8% | +81.4% | +69.0% | +43.7% | +42.3% | +43.6% | -8.9% | -14.7% | -20.2% | -19.8% | +25.7% | +30.6% | +13705.2% | +3892.0% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.71 | 6.49 | 6.22 | 5.71 | 5.54 | 6.66 | 7.63 | 7.16 | 7.38 | 8.75 | 10.49 | 11.97 | 14.27 | 7.81 | 8.84 | 9.25 | 10.65 | 12.23 | 13.80 | 15.15 | 17.17 |
| — | -2.7% | -18.4% | -20.2% | -24.9% | -23.9% | -27.3% | -40.2% | -48.3% | +12.1% | +18.7% | +29.4% | +34.0% | -36.1% | -36.0% | -38.9% | -38.0% | +122.5% | +96.6% | +672.0% | — | |
| Quick Ratio | 5.71 | 6.49 | 6.22 | 5.71 | 5.54 | 6.66 | 7.63 | 7.16 | 7.38 | 8.75 | 10.49 | 11.97 | 14.27 | 7.81 | 8.84 | 9.25 | 10.65 | 12.23 | 13.80 | 15.15 | 17.17 |
| — | -2.7% | -18.4% | -20.2% | -24.9% | -23.9% | -27.3% | -40.2% | -48.3% | +12.1% | +18.7% | +29.4% | +34.0% | -36.1% | -36.0% | -38.9% | -38.0% | +128.5% | +96.6% | +672.0% | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 23 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRBU stock.
Caribou Biosciences, Inc.'s current P/E is -0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Caribou Biosciences, Inc.'s current operating margin is -1220.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Caribou Biosciences, Inc.'s business trajectory between earnings reports.